Germany’s High-Tech Agenda backs alternative proteins with planned innovation hub

Germany’s federal government has formally embedded alternative proteins into its new High-Tech Agenda, outlining plans for a national innovation hub focused on cell cultivation and precision fermentation as part of a wider biotechnology roadmap.

• Germany’s federal government included alternative proteins in its new High-Tech Agenda and biotechnology roadmap.
• The plan proposed a national innovation hub for cell cultivation and precision fermentation in 2027.
• GFI Europe said Germany invested €79 million (US$89 million) in alternative proteins between 2020 and 2025.

The Roadmap for Biotechnology, presented by the Federal Ministry of Research, Technology, and Space, identified alternative proteins as strategically important for Germany’s innovation leadership and technological sovereignty.

The roadmap also outlined measures intended to strengthen Germany’s competitiveness in food biotechnology and accelerate commercialization pathways for emerging food technologies.

The Good Food Institute Europe welcomed the announcement, particularly plans to establish a national innovation hub for cell cultivation and precision fermentation in 2027.

The proposed hub is intended to consolidate research activities, reduce duplication, and improve collaboration between research institutions, industry, and policymakers.

GFI Europe said comparable initiatives in the UK and Sweden had demonstrated how shared research infrastructure and open-access collaboration could accelerate development of sustainable food technologies.

The organization also highlighted Germany’s strong scientific position within Europe.

According to analysis published by GFI Europe, Germany ranked first in Europe for scientific publications linked to alternative proteins and fourth for patents in recent years.

However, the group said public investment remained comparatively modest. Germany invested €79 million (US$89 million) in alternative proteins between 2020 and 2025, equivalent to less than €1 (US$1.13) per capita.

The majority of that funding focused on plant-based proteins, while only around one-fifth supported biotechnologically produced foods including cultivated meat and fermentation-derived ingredients.

The roadmap specifically highlighted technologies such as cell cultivation and advanced fermentation as having significant potential for producing sustainable foods, including cultivated meat and ingredients designed to improve the flavor and nutritional performance of plant-based products.

GFI Europe said increased public investment in the sector could generate substantial economic returns.

The organization cited analysis from consulting firm Systemiq estimating that alternative proteins could contribute between €20 billion and €65 billion (US$22.6 billion-US$73.5 billion) annually to Germany’s economy by 2045 while creating between 115,000 and 250,000 jobs, depending on political and financial support levels.

The roadmap also addressed regulatory frameworks for novel foods.

GFI Europe welcomed references to improving implementation of the EU Novel Food Regulation and proposals for the EU Biotech Act to include regulatory sandboxes covering novel foods.

The organization said transparent and efficient regulatory pathways would be critical for enabling commercialization while maintaining food safety standards.

“The inclusion of cultivated meat and precision fermentation in the high-tech agenda is a first crucial step towards implementing the coalition agreement’s plan to advance sustainable alternative proteins,” said Ivo Rzegotta, Germany, Austria and Switzerland Lead at GFI Europe.

“To support the impact of this plan on Germany’s innovation power and technological sovereignty, it is now crucial that the announced innovation hub is secured with sufficient funding and that it is designed in an interdisciplinary manner with industry participation.”

“It is encouraging that the roadmap highlights the role of efficient and transparent approval processes and calls for the EU Biotech Act to include the possibility of establishing regulatory sandboxes for novel foods,” he added.